Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George R Simon

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
JTO Clinical and Research Reports|September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA GenotypingMarissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring responseSahar A Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, et al.
Journal of Immunotherapy and Precision Oncology|April 16, 2025
PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017-2021Mehmet Altan, Dawen Sui, Cai Xu, et al.
Cancer|May 19, 2017
Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapyJessica P Hwang, Maria E Suarez-Almazor, Scott B Cantor, et al.
Nature Communications|January 3, 2025
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trialJeffrey M Clarke, George R Simon, Hirva Mamdani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2018
Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort StudyJessica P Hwang, Anna S Lok, Michael J Fisch, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung CancerJames W Welsh, John V Heymach, Dawei Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosingPaula M Fracasso, Howard Burris, Matthew A Arquette, et al.
ESMO Open|October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignanciesAparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.
JAMA Network Open|January 28, 2026
Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung CancerChiharu Sako, Brenda F Kurland, Taly G Schmidt, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
JTO Clinical and Research Reports|September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA GenotypingMarissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring responseSahar A Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, et al.
Journal of Immunotherapy and Precision Oncology|April 16, 2025
PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017-2021Mehmet Altan, Dawen Sui, Cai Xu, et al.
Cancer|May 19, 2017
Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapyJessica P Hwang, Maria E Suarez-Almazor, Scott B Cantor, et al.
Nature Communications|January 3, 2025
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trialJeffrey M Clarke, George R Simon, Hirva Mamdani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2018
Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort StudyJessica P Hwang, Anna S Lok, Michael J Fisch, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung CancerJames W Welsh, John V Heymach, Dawei Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosingPaula M Fracasso, Howard Burris, Matthew A Arquette, et al.
ESMO Open|October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignanciesAparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.
JAMA Network Open|January 28, 2026
Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung CancerChiharu Sako, Brenda F Kurland, Taly G Schmidt, et al.
Pageof 8